I ja mislim da nam je Oxford najrealnija opcija, a oni imaju milijardu doza vec spremnu. Bogate zemlje tesko da ce se odluciti zbog nize efikasnosti. Samo da hoce EMA odobriti bar do kraja mjeseca.last mohicans wrote: ↑22/01/2021 17:07 Generalno, svi su se razletili za Pfizer i Moderninom vakcinom. Ja bih volio da mi i Oxforda nabavimo,ako išta nabavimo. Dok se počne cijepiti stanovništvo, da Bog da i do ljeta, imat cemo vjerovatno vise opcija. O ovim ostalim vakcinama slabo ima informacija, dokle su, Johnson$Johnson?
A J&J su zavrsili fazu 1/2 i dobri su rezultati. Trebaju objaviti rezultate trece faze krajem januara
The Company anticipates announcing topline Phase 3 data for its single-dose Janssen COVID-19 vaccine candidate in late January 2021; however, as this trial is dependent on disease events, the timing is approximate. If the single-dose vaccine is shown to be safe and effective, the Company expects to submit an application for Emergency Use Authorization with the U.S. Food and Drug Administration shortly afterwards, with other regulatory applications around the world to be made subsequently.
https://www.jnj.com/johnson-johnson-cov ... f-medicine





